Federation des caisses Desjardins du Quebec’s Grace Therapeutics GRCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $93 | Buy |
41
+40
| +4,000% | +$111 | ﹤0.01% | 2966 |
|
|
2026
Q1 | $5 | Hold |
1
| – | – | ﹤0.01% | 2951 |
|
|
2025
Q4 | $3 | Hold |
1
| – | – | ﹤0.01% | 2872 |
|
|
2025
Q3 | $3 | Hold |
1
| – | – | ﹤0.01% | 2870 |
|
|
2025
Q2 | $3 | Hold |
1
| – | – | ﹤0.01% | 2715 |
|
|
2025
Q1 | $2 | Sell |
1
-27
| -96% | -$85 | ﹤0.01% | 2655 |
|
|
2024
Q4 | $105 | Hold |
28
| – | – | ﹤0.01% | 2483 |
|
|
2024
Q3 | $84 | Hold |
28
| – | – | ﹤0.01% | 2502 |
|
|
2024
Q2 | $82 | Hold |
28
| – | – | ﹤0.01% | 2389 |
|
|
2024
Q1 | $96 | Hold |
28
| – | – | ﹤0.01% | 2333 |
|
|
2023
Q4 | $81 | Hold |
28
| – | – | ﹤0.01% | 2310 |
|
|
2023
Q3 | $78 | Sell |
28
-2
| -7% | -$5 | ﹤0.01% | 2325 |
|
|
2023
Q2 | $94 | Sell |
30
-1
| -3% | -$3 | ﹤0.01% | 2275 |
|
|
2023
Q1 | $85 | Hold |
31
| – | – | ﹤0.01% | 2289 |
|
|
2022
Q4 | $89 | Hold |
31
| – | – | ﹤0.01% | 2428 |
|
|
2022
Q3 | $101 | Sell |
31
-7
| -18% | -$34 | ﹤0.01% | 2468 |
|
|
2022
Q2 | $198 | Hold |
38
| – | – | ﹤0.01% | 2485 |
|
|
2022
Q1 | $276 | Hold |
38
| – | – | ﹤0.01% | 2497 |
|
|
2021
Q4 | $287 | Hold |
38
| – | – | ﹤0.01% | 2486 |
|
|
2021
Q3 | $449 | Sell |
38
-3
| -7% | -$59 | ﹤0.01% | 2495 |
|
|
2021
Q2 | $1.1K | Hold |
41
| – | – | ﹤0.01% | 2432 |
|
|
2021
Q1 | $1.18K | Hold |
41
| – | – | ﹤0.01% | 2363 |
|
|
2020
Q4 | $633 | Sell |
41
-3
| -7% | -$35 | ﹤0.01% | 2254 |
|
|
2020
Q3 | $417 | Hold |
44
| – | – | ﹤0.01% | 2089 |
|
|
2020
Q2 | $970 | Hold |
44
| – | – | ﹤0.01% | 1989 |
|
|
2020
Q1 | $728 | Hold |
44
| – | – | ﹤0.01% | 2087 |
|
|
2019
Q4 | $5.03K | Hold |
44
| – | – | ﹤0.01% | 2022 |
|
|
2019
Q3 | $3.8K | Sell |
44
-808
| -95% | -$74.8K | ﹤0.01% | 2013 |
|
|
2019
Q2 | $45.6K | Buy |
852
+79
| +10% | +$3.47K | ﹤0.01% | 1514 |
|
|
2019
Q1 | $36.9K | Hold |
773
| – | – | ﹤0.01% | 1387 |
|
|
2018
Q4 | $31K | Sell |
773
-250
| -24% | -$10.9K | ﹤0.01% | 1394 |
|
|
2018
Q3 | $63K | Hold |
1,023
| – | – | ﹤0.01% | 1289 |
|
|
2018
Q2 | $28K | Hold |
1,023
| – | – | ﹤0.01% | 1488 |
|
|
2018
Q1 | $49.5K | Buy |
1,023
+979
| +2,225% | +$48.3K | ﹤0.01% | 1334 |
|
|
2017
Q4 | $2.02K | Hold |
44
| – | – | ﹤0.01% | 1997 |
|
|
2017
Q3 | $3K | Hold |
44
| – | – | ﹤0.01% | 1908 |
|
|
2017
Q2 | $2.78K | Hold |
44
| – | – | ﹤0.01% | 1976 |
|
|
2017
Q1 | $2.72K | Buy |
+44
| New | +$2.7K | ﹤0.01% | 1628 |
|
Other funds holding GRCE
EP
MS
BC
CF
XT
Federation des caisses Desjardins du Quebec's GRCE Position: Q2 2026 in Review
Federation des caisses Desjardins du Quebec increased its Grace Therapeutics (GRCE) stake by 4,000% in Q2 2026, buying an estimated $111 and bringing the position to 41 shares worth $93. The position accounts for ﹤0.01% of the portfolio, ranked #2966.
Federation des caisses Desjardins du Quebec first reported a position in GRCE in Q1 2017 and has held it in 38 quarters since. The position peaked at $63K in Q3 2018. 31 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.
- Federation des caisses Desjardins du Quebec held 41 shares of Grace Therapeutics worth $93 as of Q2 2026.
- Federation des caisses Desjardins du Quebec bought 40 Grace Therapeutics shares in Q2 2026, an estimated $111.
- Grace Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #2966 holding.
- Federation des caisses Desjardins du Quebec first reported a position in Grace Therapeutics in Q1 2017 and has held it in 38 quarters since.
- Federation des caisses Desjardins du Quebec's Grace Therapeutics position peaked at $63K in Q3 2018.
- 31 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.
Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.